Immusoft Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$4.58M
- Investors
-
28
Immusoft General Information
Description
Developer of novel therapies designed for the treatment of rare diseases. The company develops autologous cell therapies based on its immune system programming technology that entails collecting a type of the patient's immune cells, called B cells which can turn into bio factories each of which manufactures and secretes various antibodies, enabling the medical community to combat infectious diseases.
Contact Information
Website
www.immusoft.comCorporate Office
- 454 North 34th Street
- Seattle, WA 98103
- United States
Corporate Office
- 454 North 34th Street
- Seattle, WA 98103
- United States
Immusoft Timeline
Immusoft Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC (Series B) | 15-Mar-2025 | $4.58M | Completed | Clinical Trials - Phase 1 | ||
| 13. Grant | 29-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
| 12. Secondary Transaction - Private | 30-May-2022 | Completed | Clinical Trials - Phase 1 | |||
| 11. Grant | 23-Nov-2021 | Completed | Clinical Trials - Phase 1 | |||
| 10. Later Stage VC (Series B) | 02-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 9. Grant | 30-Sep-2020 | Completed | Clinical Trials - Phase 1 | |||
| 8. Grant | 25-Sep-2020 | Completed | Clinical Trials - Phase 1 | |||
| 7. Debt - PPP | 13-Apr-2020 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series B) | 01-Jan-2020 | $33M | $39.9M | Completed | Clinical Trials - Phase 1 | |
| 5. Grant | 05-Sep-2018 | $3.59M | $6.92M | Completed | Clinical Trials - Phase 1 |
Immusoft Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | 915,356 | $0.000100 | $0.02 | $0.33 | $0.33 | 1x | $0.33 | 0.53% |
| Series A | 1,865,653 | $0.000100 | $0.02 | $0.15 | $0.15 | 1x | $0.15 | 1.09% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Immusoft Comparisons
Industry
Financing
Details
Immusoft Competitors (42)
One of Immusoft’s 42 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY | ||||
| Selecta Biosciences | Formerly VC-backed | Watertown, MA |
Immusoft Patents
Immusoft Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026085108-A2 | B cell compositions and methods of use | Pending | 14-Oct-2024 | ||
| WO-2026085108-A3 | B cell compositions and methods of use | Pending | 14-Oct-2024 | ||
| EP-4836799-A2 | Glp-1 expressing modified b cells for the treatment of metabolic disease | Pending | 05-Jan-2024 | ||
| WO-2025147573-A2 | Glp-1 expressing modified b cells for the treatment of metabolic disease | Inactive | 05-Jan-2024 | ||
| WO-2025147573-A3 | Glp-1 expressing modified b cells for the treatment of metabolic disease | Inactive | 05-Jan-2024 | C12N5/0635 |
Immusoft Signals
Immusoft Investors (28)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioRock Ventures | Venture Capital | Minority | ||
| Biovision Ventures | Venture Capital | Minority | ||
| Michigan Capital Network | Venture Capital | Minority | ||
| NYBC Ventures | Corporate Venture Capital | Minority | ||
| RV Invest | Corporate Venture Capital | Minority |
Immusoft Investments & Acquisitions (2)
Immusoft’s most recent deal was a Corporate Asset Purchase with Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells). The deal was made on 27-Mar-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) | 27-Mar-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Discoverygenomics.net | 08-Mar-2016 | Merger/Acquisition | Drug Delivery |
Immusoft FAQs
-
When was Immusoft founded?
Immusoft was founded in 2009.
-
Where is Immusoft headquartered?
Immusoft is headquartered in Seattle, WA.
-
What is the size of Immusoft?
Immusoft has 22 total employees.
-
What industry is Immusoft in?
Immusoft’s primary industry is Drug Discovery.
-
Is Immusoft a private or public company?
Immusoft is a Private company.
-
What is the current valuation of Immusoft?
The current valuation of Immusoft is .
-
What is Immusoft’s current revenue?
The current revenue for Immusoft is .
-
How much funding has Immusoft raised over time?
Immusoft has raised $54.8M.
-
Who are Immusoft’s investors?
BioRock Ventures, Biovision Ventures, Michigan Capital Network, NYBC Ventures, and RV Invest are 5 of 28 investors who have invested in Immusoft.
-
Who are Immusoft’s competitors?
Marengo Therapeutics, Centrose, Inovio Pharmaceuticals, Attune Pharmaceuticals, and Selecta Biosciences are some of the 42 competitors of Immusoft.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process